Nusinersen, an ASO that causes integration of exon 7 into SMN2 mRNA enhancing full-length SMN protein expression in patients with spinal muscular atrophy (SMA), is now licensed for clinical use in a number of countries worldwide. Here, SMN2 is linked to proximal spinal muscular atrophy.